Support 100% Independent Research With Our 7-Day Free Trial
Mirum Pharmaceuticals (NASDAQ:MIRM) is making big moves. In early December 2025, the company announced its plan to acquire privately held Bluejay Therapeutics in a deal worth up to $820 million. The proposed transaction includes $250 million in cash, $370 million in Mirum common stock, and up to $200 million in tiered sales-based milestones. This acquisition is about more than just financials. It’s a bold play to deepen Mirum’s rare disease portfolio and solidify its footprint in liver disease, specifically through Bluejay’s lead asset, brelovitug. The monoclonal antibody is currently in Phase III trials for chronic hepatitis delta virus (HDV), a severe condition that lacks FDA-approved therapies.
Mirum has had a standout 2025, reporting nearly 50% year-over-year revenue growth, becoming cash flow positive, and advancing a pipeline with four registrational readouts expected in the next 18 months. So the timing of the proposed Mirum Bluejay Acquisition is no coincidence. But what makes this deal tick? Let’s explore the potential synergies and strategic drivers behind this headline-grabbing move.
Deepening The Rare Disease Pipeline With A Late-Stage Asset
At the heart of the Mirum Bluejay Acquisition is brelovitug, Bluejay’s investigational monoclonal antibody for HDV. This isn’t just another early-stage asset. It has Breakthrough Therapy designation from the FDA and PRIME designation from the EMA. That’s regulatory shorthand for “this could be a big deal.”
Brelovitug targets hepatitis B surface antigens to reduce HDV viral load. It demonstrated a 100% virologic response rate in Phase II, with 65%-82% of patients achieving the composite endpoint of viral reduction plus ALT normalization. These are not small numbers, especially in a disease with high mortality and no FDA-approved treatments.
For Mirum, this means an immediate leap in its late-stage pipeline. The AZURE Phase III program is already underway, with top-line interim data from AZURE 1 expected in Q2 2026. That timeline is crucial. With existing trials in PSC, PBC, and cholestatic pruritus also maturing, Mirum could soon be looking at multiple BLA submissions in quick succession.
From a risk management standpoint, late-stage derisked assets offer more predictable development timelines and revenue visibility. In other words, this acquisition doesn’t just boost Mirum’s science—it smooths out the business strategy.
Leveraging Mirum’s Existing Commercial Infrastructure
Another major synergy is commercial overlap. Mirum’s current portfolio—including LIVMARLI, CHOLBAM, and CTEXLI—already plays in the rare liver disease space. Adding brelovitug, which targets hepatitis delta, offers cross-pollination without starting from scratch.
In the U.S., about 15,000 HDV patients are currently diagnosed, insured, and under care. While that’s a small number, the disease is geographically concentrated in seven states and managed in urban centers. Conveniently, these are the same regions where Mirum already has sales and medical teams on the ground.
Internationally, Mirum has commercial operations across Europe and a robust distributor network covering over 30 countries. Brelovitug’s Phase III design includes head-to-head comparisons with bulevirtide, the only approved therapy in Europe. That gives Mirum competitive footing to go toe-to-toe with Gilead, should Hepcludex gain U.S. approval.
Rather than hiring and training entirely new teams, Mirum expects to add only modest headcount in areas like infectious disease and select internal medicine. That’s the kind of operational leverage investors love—revenue expansion without proportional expense growth.
Strengthening Financial Independence While Funding Growth
One of the understated benefits of the Mirum Bluejay Acquisition is its alignment with Mirum’s capital strategy. The company closed a $200 million private placement alongside the acquisition announcement. That’s money that cushions the upfront cash component while preserving balance sheet flexibility.
Mirum has also guided for $500 to $510 million in full-year 2025 revenue and ended Q3 with a $378 million cash position. It’s already GAAP profitable and expects to return to sustained cash flow positivity by 2027. Even with the additional costs of the AZURE trial and manufacturing scale-up, Mirum isn’t overextending itself.
Looking at valuation, Mirum trades at a trailing EV/revenue multiple of 7.28x and a forward EV/revenue of 5.92x. LTM EV/EBITDA stands deeply negative at -195.44x, which is common for high-growth biotechs with ongoing R&D expenses. However, forward EV/EBITDA is a more palatable 55.04x, suggesting improved operating leverage is already priced in.
By funding part of the acquisition with equity and supplementing it with fresh capital, Mirum is keeping optionality intact. That matters when you’re running multiple registrational programs with peak sales potential over $4 billion.
Expanding Market Opportunity & Long-Term Commercial Potential
Brelovitug could unlock significant new markets. Mirum estimates the global addressable population for hepatitis delta at 230,000 patients, with at least 40,000 in the U.S. That’s a sizable opportunity for a rare disease drug.
The company believes brelovitug could generate at least $750 million in global peak revenue. Its ease of use—single agent, subcutaneous administration, favorable safety profile—could make it especially competitive. Unlike some combo therapies in development, brelovitug avoids the complexity of co-formulations, which often come with manufacturing and adherence challenges.
Additionally, increased diagnosis rates could serve as a long-term growth lever. In Europe, diagnosis rates improved after the approval of bulevirtide and the introduction of reflex testing. A similar dynamic could unfold in the U.S. if more treatment options become available. This makes brelovitug not just a treatment, but potentially a market-activating product.
And while the Phase II results look strong, Mirum isn’t counting chickens. Final data from AZURE 1 and 4 are expected in H2 2026. EMA-focused trials (AZURE 2 and 3) extend the timeline into 2028, but offer broader access and pricing potential across Europe.
Final Thoughts: Strategic Fit Or Strategic Risk?
The proposed Mirum Bluejay Acquisition looks, on the surface, like a clean strategic fit. It bolsters Mirum’s rare liver disease pipeline, adds a late-stage asset with compelling Phase II data, and leverages existing commercial infrastructure. There’s also a capital cushion in place to help fund the work ahead.
But there are caution flags too. Mirum is still in its scale-up phase. Despite profitability in Q3 2025, the company is trading at a lofty LTM EV/Revenue multiple of 7.28x and has deep negative EBITDA on a trailing basis. With a forward EV/EBITDA of 55x, expectations are clearly built in. That means execution risk is real. Delays or unexpected trial results could materially impact investor sentiment.
Also, hepatitis delta remains a niche indication. While pricing and margins could be attractive, payer dynamics and competing therapies (like Gilead’s Hepcludex or Vir’s siRNA combos) could create headwinds. Not to mention the challenge of driving diagnosis in a largely invisible patient population.
So is this a bold bet or a prudent expansion? Maybe it’s a bit of both. What’s clear is that the Mirum Bluejay Acquisition has the potential to reshape the company’s trajectory—whether that tilt is up or sideways depends on what comes next.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
